<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5d135044-5ff9-180a-e053-2991aa0ab763"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Etodolac Extended-Release 600mg Tablets, USP (Repackaged)</title>
   <effectiveTime value="20171103"/>
   <setId root="55df91c5-d3cc-3443-e054-00144ff8d46c"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="021420944"/>
            <name>California Pharmaceuticals, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="021420944"/>
                        <name>California Pharmaceuticals, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70332-320" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="5d13c8b4-3d30-8bf4-e053-2991aa0a3710"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20171103"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70332-320" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Etodolac</name>
                        <formCode code="C42930" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Etodolac</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="68382-273" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="22ADO53M6F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="47MLB0F1MV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOLS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="600"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2M36281008" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETODOLAC</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2M36281008" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETODOLAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="7" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70332-320-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43176" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, UNIT-DOSE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20170803"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70332-320-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43176" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, UNIT-DOSE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20170803"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091134" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170803"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText>BLUE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>OVAL</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">273</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="5d135044-602d-180a-e053-2991aa0ab763"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <effectiveTime value="20160607"/>
               <component>
                  <section ID="ID2">
                     <id root="5d135044-6021-180a-e053-2991aa0ab763"/>
                     <title>Cardiovascular Thrombotic Events</title>
                     <text>
                        <paragraph ID="ID224">
                           <content styleCode="bold">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Cardiovascular Thrombotic Events</content>
                        </paragraph>
                        <paragraph>         
         
 
  <content styleCode="bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [
          
  
   <content styleCode="italics">see Warnings and Precautions</content> ]. 
         
 
  </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Etodolac extended-release      tablets are contraindicated in the setting of coronary artery bypass graft      (CABG) surgery [
           
   
    <content styleCode="italics">see Contraindications and Warnings and Precautions</content> ]
           
   
    <content styleCode="italics">.</content>
                              </content>
                           </item>
                        </list>
                        <paragraph ID="ID4">
                           <content styleCode="bold">Gastrointestinal Bleeding, Ulceration, and Perforation </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [
          
  
   <content styleCode="italics">see Warnings and Precautions</content>].
         
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160607"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID8">
               <id root="5d135044-602e-180a-e053-2991aa0ab763"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Etodolac extended-release tablets, USP contain etodolac, which is a member of the pyranocarboxylic acid group of non-steroidal anti-inflammatory drugs (NSAIDs). Each tablet contains etodolac for oral administration. Etodolac is a racemic mixture of [+]S and [-]R-enantiomers. Etodolac, USP is a white to off-white crystalline powder, insoluble in water but soluble in alcohols, chloroform, dimethyl sulfoxide, and aqueous polyethylene glycol.</paragraph>
                  <paragraph>The chemical name is (±) 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid. It has the following structural formula:</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_55df1359-3bcc-20bf-e054-00144ff8d46c"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>C 
  <sub>17</sub>H 
  <sub>21</sub>NO 
  <sub>3</sub> M.W. 287.36
 </paragraph>
                  <paragraph>Each etodolac extended-release tablet, USP intended for oral administration contains 600 mg of etodolac. In addition, each tablet contains the following inactive ingredients: disodium hydrogen phosphate, ethylcellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, talc, titanium dioxide and triacetin. Additionally, each 600 mg tablet contains: FD&amp;C blue # 2 aluminum lake, iron oxide red and iron oxide yellow.</paragraph>
                  <paragraph>The USP Drug Release test complies with USP Dissolution Test 1.</paragraph>
               </text>
               <effectiveTime value="20170629"/>
               <component>
                  <observationMedia ID="img_55df1359-3bcc-20bf-e054-00144ff8d46c">
                     <text>etodolac-01</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="etodolac-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID12">
               <id root="5d135044-602f-180a-e053-2991aa0ab763"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20160120"/>
               <component>
                  <section ID="ID13">
                     <id root="5d135044-6022-180a-e053-2991aa0ab763"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID14">Etodolac extended-release tablets are a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of etodolac extended-release tablets, like that of other NSAIDs, is not completely understood, but may be related to prostaglandin synthetase inhibition.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID15">
                     <id root="5d135044-6023-180a-e053-2991aa0ab763"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID16">
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption</content>
                           </content>
                        </paragraph>
                        <paragraph>Etodolac extended-release tablets and etodolac tablets both contain etodolac, but differ in their release characteristics. The systemic availability of etodolac from etodolac extended-release tablets is generally greater than 80%. Etodolac does not undergo significant first-pass metabolism following oral administration. After oral administration of etodolac extended-release tablets in doses up to 800 mg once daily, peak concentrations occur approximately 6 hours after dosing and are dose proportional for both total and free etodolac.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1 </content>shows the comparison of etodolac pharmacokinetic parameters after the administration of etodolac tablets and etodolac extended-release tablets.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2 </content>shows the etodolac pharmacokinetic parameters in various populations. The data from patients with renal and hepatic impairment were obtained following administration of (immediate-release) etodolac tablets.
        

 </paragraph>
                        <table ID="ID17" width="100%">
                           <caption>Table 1</caption>
                           <col width="49%"/>
                           <col width="22%"/>
                           <col width="29%"/>
                           <thead>
                              <tr>
                                 <td align="left" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Mean </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">CV</content>
                                    <content styleCode="bold">)%
             
     
      <footnote ID="ID17_1">% Coefficient of variation</footnote>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Pharmacokinetic </content>
                                    <content styleCode="bold">Parameters</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Etodolac </content>
                                    <content styleCode="bold">Tablets</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Etodolac </content>
                                    <content styleCode="bold">Extended</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">release </content>
                                    <content styleCode="bold">Tablets</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Extent of Oral Absorption (Bioavailability) [F]
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">≥ 80%
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">≥ 80%
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Time to Peak Concentration (Tmax), h
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">1.4 (61%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">6.7 (47%)
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Oral Clearance (CL/F), mL/h/kg
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">49.1 (33%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">46.8 (37%)
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Apparent Volume of Distribution (Vd/F), mL/kg
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">393 (29%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">566 (26%)
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Terminal Half-Life (t1/2), h
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">6.4 (22%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">8.4 (30%)
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID18" width="100%">
                           <caption>Table 2 Mean (CV%)
          
  
   <sup>*</sup> Pharmacokinetic Parameters of Etodolac in Normal Healthy Adults and Various Special Populations
         
 
  </caption>
                           <col width="14%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <col width="11%"/>
                           <col width="11%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <thead>
                              <tr>
                                 <td align="left" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="4" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Etodolac </content>
                                    <content styleCode="bold">Extended</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">release </content>
                                    <content styleCode="bold">Tablets</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="4" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Etodolac </content>
                                    <content styleCode="bold">Tablets</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="9">
                                    <paragraph styleCode="Footnote">
                                       <sup>*</sup> % Coefficient of variation 
             
     
      <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="9">
                                    <paragraph styleCode="Footnote">
                                       <sup>†</sup> Pharmacokinetic parameters obtained following administration of etodolac tablets 
             
     
      <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="9">
                                    <paragraph styleCode="Footnote">
                                       <sup>‡</sup> Age range (years)
             
     
      <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="9">
                                    <paragraph styleCode="Footnote">NA = not available
             
     
      <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">PK</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Parameters</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Normal</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Healthy</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Adults</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Healthy</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Males</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Healthy</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Females</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Elderly</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(&gt; </content>
                                    <content styleCode="bold">65 </content>
                                    <content styleCode="bold">yr</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Hemodialysis</content>
                                    <content styleCode="bold">
                                       <sup>†</sup>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">24 </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">65</content>
                                    <content styleCode="bold">) </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n </content>
                                    <content styleCode="bold">= </content>
                                    <content styleCode="bold">9</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Renal</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Impairment</content>
                                    <content styleCode="bold">
                                       <sup>†</sup>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Hepatic</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Impairment</content>
                                    <content styleCode="bold">
                                       <sup>†</sup>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">18 </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">44</content>
                                    <content styleCode="bold">)
             
     
      <sup>‡</sup>
                                    </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n </content>
                                    <content styleCode="bold">= </content>
                                    <content styleCode="bold">116</content>
                                    <content styleCode="bold">) </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">18 </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">43</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n </content>
                                    <content styleCode="bold">= </content>
                                    <content styleCode="bold">102</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">25 </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">44</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n </content>
                                    <content styleCode="bold">= </content>
                                    <content styleCode="bold">14</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">66 </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">88</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n </content>
                                    <content styleCode="bold">= </content>
                                    <content styleCode="bold">24</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Dialysis </content>
                                    <content styleCode="bold">On</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Dialysis </content>
                                    <content styleCode="bold">Off</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">46 </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">73</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n </content>
                                    <content styleCode="bold">= </content>
                                    <content styleCode="bold">10</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">34 </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">60</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n </content>
                                    <content styleCode="bold">= </content>
                                    <content styleCode="bold">9</content>
                                    <content styleCode="bold">) </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Tmax, h
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">6.7 (47%)
            
    
     <sup>*</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">6.8 (45%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">4.5 (56%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">6.2 (51%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">1.7 (88%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">0.9 (67%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">2.1 (46%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">1.1 (15%)
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Oral Clearance,
            
    
     <br/>mL/h/kg (CL/F)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">46.8 (37%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">46.8 (37%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">47.2 (38%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">51.6 (40%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">NA
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">NA
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">58.3 (19%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">42 (43%)
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Apparent
            
    
     <br/>Volume of
            
    
     <br/>Distribution,
            
    
     <br/>mL/kg (Vd/F)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">566 (26%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">580 (26%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">459 (28%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">552 (34%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">NA
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">NA
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">NA
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">NA
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Terminal Half-
            
    
     <br/>Life, h
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">8.4 (30%) 
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">8.4 (29%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">7.6 (45%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">7.8 (26%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">5.1 (22%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">7.5 (34%)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">NA
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">5.7 (24%) 
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID19">
                     <id root="5d135044-6024-180a-e053-2991aa0ab763"/>
                     <title>Food/Antacid Effects</title>
                     <text>
                        <paragraph ID="ID20">Food has no significant effect on the extent of etodolac extended-release tablets absorption, however, food significantly increased C
         
 
  <sub>max</sub> (54%) following a 600 mg dose.
        

 </paragraph>
                        <paragraph>The extent of absorption of etodolac is not affected when etodolac is administered with antacid. Coadministration, with an antacid, decreases the peak concentration reached by about 15 to 20% with no measurable effect on time-to-peak.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID21">
                     <id root="5d135044-6025-180a-e053-2991aa0ab763"/>
                     <title>Distribution</title>
                     <text>
                        <paragraph ID="ID22">The mean apparent volume of distribution (Vd/F) of etodolac following administration of etodolac extended-release tablets is 566 mL/kg. Etodolac is more than 99% bound to plasma proteins, primarily to albumin, and is independent of etodolac concentration over the dose range studied. It is not known whether etodolac is excreted in human milk. However, based on its physical-chemical properties, excretion into breast milk is expected.</paragraph>
                     </text>
                     <effectiveTime value="20160120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID23">
                     <id root="5d135044-600c-180a-e053-2991aa0ab763"/>
                     <title>Metabolism</title>
                     <text>
                        <paragraph ID="ID24">Etodolac metabolites do not contribute significantly to the pharmacological activity of etodolac extended-release tablets.</paragraph>
                        <paragraph>Following administration of immediate-release etodolac, several metabolites have been identified in human plasma and urine. Other metabolites remain to be identified. The metabolites include 6-, 7-, and 8-hydroxylated etodolac and etodolac glucuronide. After a single dose of 
         
 
  <sup>14</sup>C-etodolac, hydroxylated metabolites accounted for less than 10% of total drug in serum. On chronic dosing, hydroxylated-etodolac metabolites do not accumulate in the plasma of patients with normal renal function. The extent of accumulation of hydroxylated-etodolac metabolites in patients with renal dysfunction has not been studied. The role, if any, of a specific cytochrome P450 system in the metabolism of etodolac is unknown. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID25">
                     <id root="5d135044-600d-180a-e053-2991aa0ab763"/>
                     <title>Excretion</title>
                     <text>
                        <paragraph ID="ID26">The mean oral clearance of etodolac following oral etodolac extended-release tablets dosing is 47 (±17) mL/h/kg. The terminal half-life (t
         
 
  <sub>1/2</sub>) of etodolac after etodolac extended-release tablets administration is 8.4 hours compared to 6.4 hours for etodolac tablets. Approximately 1% of an etodolac tablet dose is excreted unchanged in the urine, with 72% of the dose excreted into the urine as parent drug plus metabolites:
        

 </paragraph>
                        <table ID="ID27" width="100%">
                           <col width="88%"/>
                           <col width="12%"/>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode=" Lrule Toprule" valign="top">- etodolac, unchanged
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Rrule Toprule" valign="top">1% 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule" valign="top">- etodolac glucuronide
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Rrule" valign="top">13% 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule" valign="top">- hydroxylated metabolites (6-, 7-, and 8-OH)
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Rrule" valign="top">5% 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule" valign="top">- hydroxylated metabolite glucuronides
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Rrule" valign="top">20% 
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Botrule" valign="top">- unidentified metabolites
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Rrule Botrule" valign="top">33% 
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID28">Fecal excretion accounted for 16% of the dose.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID29">
                     <id root="5d135044-600e-180a-e053-2991aa0ab763"/>
                     <title>Special Populations</title>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID30">
                     <id root="5d135044-6017-180a-e053-2991aa0ab763"/>
                     <title>Geriatric</title>
                     <text>
                        <paragraph ID="ID31">In clinical studies, age was not shown to have any effect on half-life or protein binding, and demonstrated no change in expected drug accumulation. No dosage adjustment is generally necessary in the elderly on the basis of pharmacokinetics. The elderly may need dosage adjustment, however, as they may be more sensitive to antiprostaglandin effects than younger patients (see 
         
 
  <content styleCode="bold">
                              <linkHtml href="#ID70">PRECAUTIONS</linkHtml>, 
          
  
   <linkHtml href="#ID114">Geriatric Use</linkHtml>).
         
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID32">
                     <id root="5d135044-6018-180a-e053-2991aa0ab763"/>
                     <title>Pediatric</title>
                     <text>
                        <paragraph ID="ID33">The pharmacokinetics of etodolac extended-release tablets were assessed in an open-label, 12 week clinical trial which included plasma sampling for population pharmacokinetics. Seventy-two (72) patients, 6 to 16 years of age, with juvenile rheumatoid arthritis, received etodolac extended-release tablets in doses of 13.3 to 21.3 mg/kg given as 400 to 1000 mg once daily. The results from a population pharmacokinetic analysis based on the 59 subjects who completed the trial are as follows:</paragraph>
                        <table ID="ID34" width="100%">
                           <caption>Table 3 Pharmacokinetic Parameter Estimates for Etodolac Extended-release Tablets in Patients with Juvenile Rheumatoid Arthritis</caption>
                           <col width="63%"/>
                           <col width="37%"/>
                           <thead>
                              <tr>
                                 <td align="left" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Parameter</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">JRA</content>
                                    <content styleCode="bold">
                                       <footnote ID="ID34_1">Mean (CV) of parameter estimates predicted from population pharmacokinetics</footnote> 
            
    
     </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">Age</content>
                                    <content styleCode="bold">:</content>
                                    <content styleCode="bold">6 </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">16</content>
                                    <content styleCode="bold">)
             
     
      <footnote ID="ID34_2">Age range (years)</footnote> 
            
    
     </content>
                                    <content styleCode="bold">n </content>
                                    <content styleCode="bold">= </content>
                                    <content styleCode="bold">59</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Oral Clearance (CL/F), mL/h/kg
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">47.8 (38%)
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Apparent Volume of Distribution (Vd/F), mL/kg
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">78.9 (61%)
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">Half-life (t1/2), h
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">12.1 (75%)
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID35">While similar, the pharmacokinetic parameters for children with juvenile rheumatoid arthritis did not directly correlate with adult pharmacokinetic data in rheumatoid arthritis. In the population pharmacokinetic analysis, body weights below 50 kg were found to correlate with CL/F (see 
         
 
  <content styleCode="bold">
                              <linkHtml href="#ID158">DOSAGE AND ADMINISTRATION</linkHtml>).
         
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID36">
                     <id root="5d135044-6019-180a-e053-2991aa0ab763"/>
                     <title>Race</title>
                     <text>
                        <paragraph ID="ID37">Pharmacokinetic differences due to race have not been identified. Clinical studies included patients of many races, all of whom responded in a similar fashion.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID38">
                     <id root="5d135044-601a-180a-e053-2991aa0ab763"/>
                     <title>Hepatic Insufficiency</title>
                     <text>
                        <paragraph ID="ID39">The pharmacokinetics of etodolac following administration of etodolac extended-release tablets have not been investigated in subjects with hepatic insufficiency. Following administration of etodolac tablets, the plasma protein binding and disposition of total and free etodolac were unchanged in the presence of compensated hepatic cirrhosis. Although no dosage adjustment is generally required in patients with chronic hepatic diseases, etodolac clearance is dependent on liver function and could be reduced in patients with severe hepatic failure.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID40">
                     <id root="5d135044-6026-180a-e053-2991aa0ab763"/>
                     <title>Renal Insufficiency</title>
                     <text>
                        <paragraph ID="ID41">The pharmacokinetics of etodolac following administration of etodolac extended-release tablets have not been investigated in subjects with renal insufficiency. Etodolac renal clearance following administration of etodolac tablets was unchanged in the presence of mild-to-moderate renal failure (creatinine clearance, 37 to 88 mL/min). Although renal elimination is a significant pathway of excretion for etodolac metabolites, no dosing adjustment in patients with mild to moderate renal dysfunction is generally necessary. Etodolac plasma protein binding decreases in patients with severe renal deficiency. Etodolac should be used with caution in such patients because, as with other NSAIDs, it may further decrease renal function in some patients. Etodolac is not significantly removed from the blood in patients undergoing hemodialysis.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID42">
               <id root="5d135044-6030-180a-e053-2991aa0ab763"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>CLINICAL STUDIES</title>
               <effectiveTime value="20140210"/>
               <component>
                  <section ID="ID43">
                     <id root="5d135044-6027-180a-e053-2991aa0ab763"/>
                     <title>Arthritis</title>
                     <text>
                        <paragraph ID="ID44">The use of etodolac extended-release tablets in managing the signs and symptoms of osteoarthritis of the knee and rheumatoid arthritis was assessed in doubleblind, randomized, parallel, controlled clinical trials in 1552 patients. In these trials, etodolac extended-release tablets, given once daily, provided efficacy comparable to immediate-release etodolac.</paragraph>
                        <paragraph>The safety, efficacy, and pharmacokinetics of etodolac extended-release tablets were assessed in an open-label, 12 week clinical trial. Seventy-two (72) patients, 6 to 16 years of age, with juvenile rheumatoid arthritis, received etodolac extended-release tablets in doses of 400 to 1000 mg (13.3 to 21.3 mg/kg body weight) once daily. At these doses, etodolac extended-release tablets controlled the signs and symptoms of juvenile rheumatoid arthritis. Based on the results of this study, the safety profile of etodolac extended-release tablets (at doses not exceeding 20 mg/kg) appeared to be similar to that observed in the adult arthritic patients in clinical trials (see 
         
 
  <content styleCode="bold">
                              <linkHtml href="#ID70">PRECAUTIONS</linkHtml>, 
          
  
   <linkHtml href="#ID112">Pediatric Use</linkHtml>).
         
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID45">
               <id root="5d135044-6031-180a-e053-2991aa0ab763"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID46">Carefully consider the potential benefits and risks of etodolac extended-release tablets, USP and other treatment options before deciding to use etodolac extended-release tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see 
       
 
  <content styleCode="bold">
                        <linkHtml href="#ID50">WARNINGS</linkHtml>).
       
 
  </content>
                  </paragraph>
                  <paragraph>Etodolac extended-release tablets, USP are indicated:</paragraph>
                  <paragraph>*    For relief of signs and symptoms of juvenile arthritis</paragraph>
                  <paragraph>*    For relief of the signs and symptoms of rheumatoid arthritis</paragraph>
                  <paragraph>*    For relief of the signs and symptoms of osteoarthritis</paragraph>
               </text>
               <effectiveTime value="20160120"/>
            </section>
         </component>
         <component>
            <section ID="ID48">
               <id root="5d135044-6032-180a-e053-2991aa0ab763"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID49">Etodolac extended-release tablets are contraindicated in patients with known hypersensitivity to etodolac.</paragraph>
                  <paragraph>Etodolac extended-release tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see 
       
 
  <content styleCode="bold">
                        <linkHtml href="#ID50">WARNINGS</linkHtml>, 
        
  
   <linkHtml href="#ID64">Anaphylactoid Reactions </linkHtml> 
       
 
  </content>and 
       
 
  <content styleCode="bold">
                        <linkHtml href="#ID70">PRECAUTIONS</linkHtml>, 
        
  
   <linkHtml href="#ID77">Preexisting Asthma</linkHtml>).
       
 
  </content>
                  </paragraph>
                  <paragraph>Etodolac extended-release tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see 
       
 
  <linkHtml href="#ID50">WARNINGS</linkHtml>).
      

 </paragraph>
               </text>
               <effectiveTime value="20160120"/>
            </section>
         </component>
         <component>
            <section ID="ID50">
               <id root="5d135044-6033-180a-e053-2991aa0ab763"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <effectiveTime value="20160120"/>
               <component>
                  <section ID="ID51">
                     <id root="5d135044-6028-180a-e053-2991aa0ab763"/>
                     <title>Cardiovascular Effects</title>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID52">
                     <id root="5d135044-6029-180a-e053-2991aa0ab763"/>
                     <title>Cardiovascular Thrombotic Events</title>
                     <text>
                        <paragraph ID="ID53">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.</paragraph>
                        <paragraph>To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.</paragraph>
                        <paragraph>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as etodolac, increases the risk of serious gastrointestinal (GI) events [
         
 
  <content styleCode="italics">see Warnings</content>].
        

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Status Post Coronary Artery Bypass Graft (CABG) Surgery</content>
                           </content>
                        </paragraph>
                        <paragraph>Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10–14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [
         
 
  <content styleCode="italics">see Contraindications</content>].
        

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Post-MI Patients</content>
                           </content>
                        </paragraph>
                        <paragraph>Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.</paragraph>
                        <paragraph>Avoid the use of etodolac extended-release tablets in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If etodolac extended-release tablets are used in patients with a recent MI, monitor patients for signs of cardiac ischemia.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hypertension</content>
                           </content>
                        </paragraph>
                        <paragraph>NSAIDs, including etodolac extended-release tablets, can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including etodolac extended-release tablets, should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Heart Failure and Edema</content>
                           </content>
                        </paragraph>
                        <paragraph>The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized</paragraph>
                        <paragraph>controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.</paragraph>
                        <paragraph>Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of etodolac may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] [see 
         
 
  <linkHtml href="#ID84">Drug Interactions</linkHtml>].
        

 </paragraph>
                        <paragraph>Avoid the use of etodolac extended-release tablets in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If etodolac extended-release tablets are used in patients with severe heart failure, monitor patients for signs of worsening heart failure.</paragraph>
                     </text>
                     <effectiveTime value="20160120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID58">
                     <id root="5d135044-600f-180a-e053-2991aa0ab763"/>
                     <title>Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation</title>
                     <text>
                        <paragraph ID="ID59">NSAIDs, including etodolac extended-release tablets, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2 to 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.</paragraph>
                        <paragraph>NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. Patients with a 
         
 
  <content styleCode="italics">prior history of peptic ulcer disease and/or gastrointestinal bleeding </content>who use NSAIDs have a greater than 10 fold increased risk for developing a GI bleed compared to patients with neither of these risk factors. Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.
        

 </paragraph>
                        <paragraph>To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID60">
                     <id root="5d135044-6010-180a-e053-2991aa0ab763"/>
                     <title>Renal Effects</title>
                     <text>
                        <paragraph ID="ID61">Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID62">
                     <id root="5d135044-6011-180a-e053-2991aa0ab763"/>
                     <title>Advanced Renal Disease</title>
                     <text>
                        <paragraph ID="ID63">No information is available from controlled clinical studies regarding the use of etodolac extended-release tablets in patients with advanced renal disease. Therefore, treatment with etodolac extended-release tablets is not recommended in these patients with advanced renal disease. If etodolac extended-release tablet therapy must be initiated, close monitoring of the patient’s renal function is advisable.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID64">
                     <id root="5d135044-601b-180a-e053-2991aa0ab763"/>
                     <title>Anaphylactoid Reactions</title>
                     <text>
                        <paragraph ID="ID65">As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to etodolac extended-release tablets. Etodolac extended-release tablets should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see 
         
 
  <content styleCode="bold">
                              <linkHtml href="#ID48">CONTRAINDICATIONS </linkHtml>
                           </content>and 
         
 
  <content styleCode="bold">
                              <linkHtml href="#ID70">PRECAUTIONS</linkHtml>, 
          
  
   <linkHtml href="#ID77">Preexisting Asthma</linkHtml>). 
         
 
  </content>Emergency help should be sought in cases where an anaphylactoid reaction occurs.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID66">
                     <id root="5d135044-601c-180a-e053-2991aa0ab763"/>
                     <title>Skin Reactions</title>
                     <text>
                        <paragraph ID="ID67">NSAIDs, including etodolac extended-release tablets, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID68">
                     <id root="5d135044-601d-180a-e053-2991aa0ab763"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph ID="ID69">In late pregnancy, as with other NSAIDs, etodolac extended-release tablets should be avoided because it may cause premature closure of the ductus arteriosus.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID70">
               <id root="5d135044-6034-180a-e053-2991aa0ab763"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20160120"/>
               <component>
                  <section ID="ID71">
                     <id root="5d135044-601e-180a-e053-2991aa0ab763"/>
                     <title>General</title>
                     <text>
                        <paragraph ID="ID72">Etodolac extended-release tablets cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.</paragraph>
                        <paragraph>The pharmacological activity of etodolac extended-release tablets in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID73">
                     <id root="5d135044-601f-180a-e053-2991aa0ab763"/>
                     <title>Hepatic Effects</title>
                     <text>
                        <paragraph ID="ID74">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including etodolac extended-release tablets. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.</paragraph>
                        <paragraph>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with etodolac extended-release tablets. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), etodolac extended-release tablets should be discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID75">
                     <id root="5d135044-6012-180a-e053-2991aa0ab763"/>
                     <title>Hematological Effects</title>
                     <text>
                        <paragraph ID="ID76">Anemia is sometimes seen in patients receiving NSAIDs, including etodolac extended-release tablets. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including etodolac extended-release tablets, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.</paragraph>
                        <paragraph>NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving etodolac extended-release tablets who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID77">
                     <id root="5d135044-6013-180a-e053-2991aa0ab763"/>
                     <title>Preexisting Asthma</title>
                     <text>
                        <paragraph ID="ID78">Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm which can be fatal. Since cross reactivity, including bronchospasm, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, etodolac extended-release tablets should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID79">
                     <id root="5d135044-6014-180a-e053-2991aa0ab763"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph ID="ID80">
                           <content styleCode="bold">Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <content styleCode="bold">Cardiovascular Thrombotic Events: </content>Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their health care provider immediately [
          
  
   <content styleCode="italics">see 
           
   
    <linkHtml href="#ID50">Warnings</linkHtml>
                              </content>].
         
 
  </item>
                           <item>Etodolac extended-release tablets, like other NSAIDs, can cause GI discomfort and, rarely, serious GI side effects, such as ulcers and bleeding, which may result in hospitalization and even death. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms including epigastric pain, dyspepsia, melena, and hematemesis. Patients should be apprised of the importance of this follow-up (see 
          
  
   <content styleCode="bold">
                                 <linkHtml href="#ID50">WARNINGS</linkHtml>
                              </content>, 
          
  
   <content styleCode="bold">Gastrointestinal Effects - Risk of Ulceration</content>, 
          
  
   <content styleCode="bold">Bleeding</content>, 
          
  
   <content styleCode="bold">and Perforation</content>).
         
 
  </item>
                           <item>Etodolac extended-release tablets, like other NSAIDs, can cause serious skin side effects such as exfoliative dermatitis, SJS, and TEN, which may result in hospitalizations and even death. Although serious skin reactions may occur without warning, patients should be alert for the signs and symptoms of skin rash and blisters, fever, or other signs of hypersensitivity such as itching, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of rash and contact their physicians as soon as possible.</item>
                           <item>
                              <content styleCode="bold">Heart Failure And Edema: </content>Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur [
          
  
   <content styleCode="italics">see 
           
   
    <linkHtml href="#ID50">Warnings</linkHtml>
                              </content>].
         
 
  </item>
                           <item>Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.</item>
                           <item>Patients should be informed of the signs of an anaphylactoid reaction (e.g., difficulty breathing, swelling of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see 
          
  
   <content styleCode="bold">
                                 <linkHtml href="#ID50">WARNINGS</linkHtml>
                              </content>).
         
 
  </item>
                           <item>In late pregnancy, as with other NSAIDs, etodolac extended-release tablets should be avoided because it will cause premature closure of the ductus arteriosus.</item>
                        </list>
                     </text>
                     <effectiveTime value="20160120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID82">
                     <id root="5d135044-6015-180a-e053-2991aa0ab763"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph ID="ID83">Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with NSAIDs, should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, etodolac extended-release tablets should be discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID84">
                     <id root="5d135044-6016-180a-e053-2991aa0ab763"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID85">
                     <id root="5d135044-6006-180a-e053-2991aa0ab763"/>
                     <title>ACE-inhibitors</title>
                     <text>
                        <paragraph ID="ID86">Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID87">
                     <id root="5d135044-6007-180a-e053-2991aa0ab763"/>
                     <title>Aspirin</title>
                     <text>
                        <paragraph ID="ID88">When etodolac extended-release tablets are administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of etodolac extended-release tablets and aspirin is not generally recommended because of the potential of increased adverse effects.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID89">
                     <id root="5d135044-6008-180a-e053-2991aa0ab763"/>
                     <title>Cyclosporine and Digoxin</title>
                     <text>
                        <paragraph ID="ID90">Etodolac extended-release tablets, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs, leading to elevated serum levels of cyclosporine and digoxin and increased toxicity. Nephrotoxicity associated with cyclosporine may also be enhanced. Patients receiving these drugs who are given etodolac extended-release tablets, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID91">
                     <id root="5d135044-6009-180a-e053-2991aa0ab763"/>
                     <title>Furosemide</title>
                     <text>
                        <paragraph ID="ID92">Clinical studies, as well as post marketing observations, have shown that etodolac extended-release tablets can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see 
         
 
  <content styleCode="bold">
                              <linkHtml href="#ID50">WARNINGS</linkHtml>, 
          
  
   <linkHtml href="#ID60">Renal Effects</linkHtml>), 
         
 
  </content>as well as to assure diuretic efficacy.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20160120"/>
                  </section>
               </component>
               <component>
                  <section ID="ID93">
                     <id root="5d135044-600a-180a-e053-2991aa0ab763"/>
                     <title>Lithium</title>
                     <text>
                        <paragraph ID="ID94">NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID95">
                     <id root="5d135044-600b-180a-e053-2991aa0ab763"/>
                     <title>Methotrexate</title>
                     <text>
                        <paragraph ID="ID96">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID97">
                     <id root="5d135044-6020-180a-e053-2991aa0ab763"/>
                     <title>Phenylbutazone</title>
                     <text>
                        <paragraph ID="ID98">Phenylbutazone causes an increase (by about 80%) in the free fraction of etodolac. Although 
         
 
  <content styleCode="italics">in vivo </content>studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.
        

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Warfarin</content>
                           </content>
                        </paragraph>
                        <paragraph>The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID99">
                     <id root="5d135044-5ffa-180a-e053-2991aa0ab763"/>
                     <title>Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph ID="ID100">The urine of patients who take etodolac can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of etodolac. Diagnostic dip-stick methodology, used to detect ketone bodies in urine, has resulted in false-positive findings in some patients treated with etodolac. Generally, this phenomenon has not been associated with other clinically significant events. No dose relationship has been observed.</paragraph>
                        <paragraph>Etodolac treatment is associated with a small decrease in serum uric acid levels. In clinical trials, mean decreases of 1 to 2 mg/dL were observed in arthritic patients receiving etodolac (600 mg to 1000 mg/day) after 4 weeks of therapy. These levels then remained stable for up to 1 year of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID101">
                     <id root="5d135044-5ffb-180a-e053-2991aa0ab763"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID102">No carcinogenic effect of etodolac was observed in mice or rats receiving oral doses of 15 mg/kg/day (45 to 89 mg/m
         
 
  <sup>2</sup>, respectively) or less for periods of 18 months or 2 years, respectively. Etodolac was not mutagenic in 
         
 
  <content styleCode="italics">in vitro </content>tests performed with   
         
 
  <content styleCode="italics">S. typhimurium </content>and mouse lymphoma cells as well as in an 
         
 
  <content styleCode="italics">in vivo </content>mouse micronucleus test. However, data from the 
         
 
  <content styleCode="italics">in vitro </content>human peripheral lymphocyte test showed an increase in the number of gaps (3% to 5% unstained regions in the chromatid without dislocation) among the etodolac-treated cultures (50 to 200 g/mL) compared to negative controls (2%); no other difference was noted between the controls and drug-treated groups. Etodolac showed no impairment of fertility in male and female rats up to oral doses of 16 mg/kg (94 mg/m
         
 
  <sup>2</sup>). However, reduced implantation of fertilized eggs occurred in the 8 mg/kg group.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID103">
                     <id root="5d135044-5ffc-180a-e053-2991aa0ab763"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID104">
                     <id root="5d135044-5ffd-180a-e053-2991aa0ab763"/>
                     <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                     <title>Teratogenic Effects</title>
                     <text>
                        <paragraph ID="ID105">
                           <content styleCode="italics">Pregnancy category C</content>
                        </paragraph>
                        <paragraph>Reproductive studies conducted in rats and rabbits have not demonstrated evidence of developmental abnormalities. However, animal reproduction studies are not always predictive of human response. There are no adequate and well-controlled studies in pregnant women.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID106">
                     <id root="5d135044-5ffe-180a-e053-2991aa0ab763"/>
                     <code code="34078-6" codeSystem="2.16.840.1.113883.6.1" displayName="NONTERATOGENIC EFFECTS SECTION"/>
                     <title>Nonteratogenic Effects</title>
                     <text>
                        <paragraph ID="ID107">Because of the known effects of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID108">
                     <id root="5d135044-5fff-180a-e053-2991aa0ab763"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>Labor and Delivery</title>
                     <text>
                        <paragraph ID="ID109">In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of etodolac extended-release tablets on labor and delivery in pregnant women are unknown.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID110">
                     <id root="5d135044-6000-180a-e053-2991aa0ab763"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph ID="ID111">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from etodolac extended-release tablets, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID112">
                     <id root="5d135044-6001-180a-e053-2991aa0ab763"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph ID="ID113">Safety and effectiveness in pediatric patients below the age of 6 years have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID114">
                     <id root="5d135044-6002-180a-e053-2991aa0ab763"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph ID="ID115">As with any NSAIDs, caution should be exercised in treating the elderly (65 years and older).</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID116">
               <id root="5d135044-6035-180a-e053-2991aa0ab763"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID117">A total of 1552 patients were exposed to etodolac extended-release tablets in controlled clinical studies of at least 4 weeks in length and using daily doses in the range of 400 to 1200 mg. In the tabulations below, adverse event rates are generally categorized based on the incidence of events in the first 30 days of treatment with etodolac extended-release tablets. As with other NSAIDs, the cumulative adverse event rates may increase significantly over time with extended therapy.</paragraph>
                  <paragraph>In patients taking NSAIDs, including etodolac extended-release tablets, the most frequently reported adverse experiences occurring in approximately 1 to 10% of patients are: </paragraph>
                  <paragraph>Gastrointestinal experiences including</paragraph>
                  <table ID="ID118" width="100%">
                     <col width="39%"/>
                     <col width="19%"/>
                     <col width="42%"/>
                     <tbody>
                        <tr>
                           <td align="left" styleCode=" Lrule Rrule Toprule" valign="top">abdominal pain
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule Toprule" valign="top">constipation
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule Toprule" valign="top">Diarrhea
          
    
     <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode=" Lrule Rrule" valign="top">dyspepsia
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule" valign="top">flatulence
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule" valign="top">GI ulcers (gastric/duodenal)*
          
    
     <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode=" Lrule Rrule Botrule" valign="top">gross bleeding/perforation
          
    
     <sup>*</sup>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule Botrule" valign="top">nausea
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule Botrule" valign="top">Vomiting
          
    
     <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID119">Other events including:</paragraph>
                  <table ID="ID120" width="100%">
                     <col width="39%"/>
                     <col width="22%"/>
                     <col width="39%"/>
                     <tbody>
                        <tr>
                           <td align="left" styleCode=" Lrule Rrule Toprule" valign="top">abnormal renal function
          
    
     <footnote ID="ID120_1">Adverse events that were observed in &lt; 1% of patients in the first 30 days of treatment with etodolac extended-release tablets in clinical trials.</footnote>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule Toprule" valign="top">Anemia
          
    
     <footnoteRef IDREF="ID120_1"/>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule Toprule" valign="top">asthenia
          
    
     <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode=" Lrule Rrule" valign="top">dizziness
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule" valign="top">edema
          
    
     <footnoteRef IDREF="ID120_1"/>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule" valign="top">elevated liver enzymes
          
    
     <footnoteRef IDREF="ID120_1"/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode=" Lrule Rrule" valign="top">headaches
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule" valign="top">hypertension
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule" valign="top">increased bleeding time
          
    
     <footnoteRef IDREF="ID120_1"/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode=" Lrule Rrule" valign="top">infection
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule" valign="top">pharyngitis
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule" valign="top">pruritus
          
    
     <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode=" Lrule Rrule Botrule" valign="top">rashes
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule Botrule" valign="top">rhinitis
          
    
     <br/>
                           </td>
                           <td align="center" styleCode=" Lrule Rrule Botrule" valign="top">tinnitus
          
    
     <footnoteRef IDREF="ID120_1"/>
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20140210"/>
               <component>
                  <section ID="ID121">
                     <id root="5d135044-6003-180a-e053-2991aa0ab763"/>
                     <title>Additional NSAID Adverse Experiences Reported Occasionally with NSAIDs or Etodolac Extended-release Tablets Include</title>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID122">
                     <id root="5d135044-6004-180a-e053-2991aa0ab763"/>
                     <title>Body as a whole</title>
                     <text>
                        <paragraph ID="ID123">Allergic reaction, anaphylactic/anaphylactoid reactions (including shock), chills, fever, sepsis</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID124">
                     <id root="5d135044-6005-180a-e053-2991aa0ab763"/>
                     <title>Cardiovascular system</title>
                     <text>
                        <paragraph ID="ID125">Congestive heart failure, flushing, palpitations, tachycardia, syncope, vasculitis (including necrotizing and allergic)</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID126">
                     <id root="5d135044-603b-180a-e053-2991aa0ab763"/>
                     <title>Digestive system</title>
                     <text>
                        <paragraph ID="ID127">Anorexia, cholestatic hepatitis, cholestatic jaundice, dry mouth, duodenitis, eructation, esophagitis, gastritis, gastric/peptic ulcers, glossitis, hepatic failure, hepatitis, hematemesis, intestinal ulceration, jaundice, liver necrosis, melena, pancreatitis, rectal bleeding, stomatitis</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID128">
                     <id root="5d135044-603c-180a-e053-2991aa0ab763"/>
                     <title>Hemic and lymphatic system</title>
                     <text>
                        <paragraph ID="ID129">Agranulocytosis, ecchymosis, eosinophilia, hemolytic anemia, leukopenia, neutropenia, pancytopenia, purpura, thrombocytopenia</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID130">
                     <id root="5d135044-603d-180a-e053-2991aa0ab763"/>
                     <title>Metabolic and nutritional</title>
                     <text>
                        <paragraph ID="ID131">Hyperglycemia in previously controlled diabetic patients</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID132">
                     <id root="5d135044-603e-180a-e053-2991aa0ab763"/>
                     <title>Nervous system</title>
                     <text>
                        <paragraph ID="ID133">Anxiety, confusion, depression, dream abnormalities, insomnia, nervousness, paresthesia, somnolence, tremors, vertigo</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Respiratory system</content>
                           </content>
                        </paragraph>
                        <paragraph>Asthma, dyspnea, pulmonary infiltration with eosinophilia</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Skin and appendages</content>
                           </content>
                        </paragraph>
                        <paragraph>Angioedema, cutaneous vasculitis with purpura, erythema multiforme, hyperpigmentation, sweating, urticaria, vesiculobullous rash</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID134">
                     <id root="5d135044-603f-180a-e053-2991aa0ab763"/>
                     <title>Special senses</title>
                     <text>
                        <paragraph ID="ID135">Blurred vision, photophobia, transient visual disturbances</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID136">
                     <id root="5d135044-6040-180a-e053-2991aa0ab763"/>
                     <title>Urogenital system</title>
                     <text>
                        <paragraph ID="ID137">Dysuria, elevated BUN, oliguria/polyuria, proteinuria, renal failure, renal insufficiency, renal papillary necrosis, serum creatinine increase, urinary frequency</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID138">
                     <id root="5d135044-6041-180a-e053-2991aa0ab763"/>
                     <title>Other NSAID Adverse Reactions, Which Occur Rarely Are</title>
                     <text>
                        <paragraph ID="ID139">
                           <content styleCode="bold">
                              <content styleCode="italics">Body as a whole</content>
                           </content>
                        </paragraph>
                        <paragraph>Anaphylactic reactions, appetite changes, death</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID140">
                     <id root="5d135044-6042-180a-e053-2991aa0ab763"/>
                     <title>Cardiovascular system</title>
                     <text>
                        <paragraph ID="ID141">Arrhythmia, cerebrovascular accident, hypotension, myocardial infarction</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID142">
                     <id root="5d135044-6043-180a-e053-2991aa0ab763"/>
                     <title>Digestive system</title>
                     <text>
                        <paragraph ID="ID143">Colitis, esophagitis with or without stricture or cardiospasm, thirst, ulcerative stomatitis</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID144">
                     <id root="5d135044-6044-180a-e053-2991aa0ab763"/>
                     <title>Hemic and lymphatic system</title>
                     <text>
                        <paragraph ID="ID145">Aplastic anemia, lymphadenopathy</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID146">
                     <id root="5d135044-6045-180a-e053-2991aa0ab763"/>
                     <title>Metabolic and nutritional</title>
                     <text>
                        <paragraph ID="ID147">Change in weight</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID148">
                     <id root="5d135044-6046-180a-e053-2991aa0ab763"/>
                     <title>Nervous system</title>
                     <text>
                        <paragraph ID="ID149">Coma, convulsions, hallucinations, meningitis</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Respiratory</content>
                           </content>
                        </paragraph>
                        <paragraph>Bronchitis, pneumonia, respiratory depression, sinusitis</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID150">
                     <id root="5d135044-6047-180a-e053-2991aa0ab763"/>
                     <title>Skin and appendages</title>
                     <text>
                        <paragraph ID="ID151">Alopecia, exfoliative dermatitis, maculopapular rash, photosensitivity, skin peeling, Stevens-Johnson syndrome, toxic epidermal necrosis</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID152">
                     <id root="5d135044-6048-180a-e053-2991aa0ab763"/>
                     <title>Special senses</title>
                     <text>
                        <paragraph ID="ID153">Conjunctivitis, deafness, hearing impairment, taste perversion</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID154">
                     <id root="5d135044-6038-180a-e053-2991aa0ab763"/>
                     <title>Urogenital system</title>
                     <text>
                        <paragraph ID="ID155">Cystitis, hematuria, interstitial nephritis, leukorrhea, renal calculus, uterine bleeding irregularities</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID156">
               <id root="5d135044-6036-180a-e053-2991aa0ab763"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID157">Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose.</paragraph>
                  <paragraph>Patients should be managed by symptomatic and supportive care following an NSAID overdose. There are no specific antidotes.</paragraph>
                  <paragraph>Emesis and/or activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose (5 to 10 times the usual dose). Forced diuresis, alkalinization of the urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.</paragraph>
               </text>
               <effectiveTime value="20140210"/>
            </section>
         </component>
         <component>
            <section ID="ID158">
               <id root="5d135044-6037-180a-e053-2991aa0ab763"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph ID="ID159">Carefully consider the potential benefits and risks of etodolac extended-release tablets and other treatment options before deciding to use etodolac extended-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see 
       
 
  <content styleCode="bold">
                        <linkHtml href="#ID50">WARNINGS</linkHtml>).
       
 
  </content>
                  </paragraph>
                  <paragraph>After observing the response to initial therapy with etodolac extended-release tablets, the dose and frequency should be adjusted to suit an individual patient’s needs.</paragraph>
               </text>
               <effectiveTime value="20140210"/>
               <component>
                  <section ID="ID160">
                     <id root="5d135044-6039-180a-e053-2991aa0ab763"/>
                     <title>Juvenile Rheumatoid Arthritis</title>
                     <text>
                        <paragraph ID="ID161">For the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 6 to 16 years of age, the recommended dose given orally once per day should be based on body weight, according to the following table:</paragraph>
                        <table ID="ID162" width="100%">
                           <caption>Table 4</caption>
                           <col width="65%"/>
                           <col width="35%"/>
                           <thead>
                              <tr>
                                 <td align="left" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Body </content>
                                    <content styleCode="bold">Weight </content>
                                    <content styleCode="bold">Range </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">kg</content>
                                    <content styleCode="bold">)</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                                 <td align="center" colspan="1" styleCode=" Lrule Rrule Botrule Toprule" valign="top">
                                    <content styleCode="bold">Dose </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">20 to 30 
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">400 mg Tablet x 1
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">31 to 45 
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">600 mg Tablet x 1
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">46 to 60 
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">400 mg Tablet x 2
            
    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode=" Lrule Rrule Botrule Toprule" valign="top">&gt; 60 
            
    
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Lrule Rrule Botrule Toprule" valign="top">500 mg Tablet x 2
            
    
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
               <component>
                  <section ID="ID163">
                     <id root="5d135044-603a-180a-e053-2991aa0ab763"/>
                     <title>Rheumatoid Arthritis and Osteoarthritis</title>
                     <text>
                        <paragraph ID="ID164">For the relief of the signs and symptoms of osteoarthritis or rheumatoid arthritis, the recommended starting dose of etodolac extended-release tablets is 400 to 1000 mg given orally once per day.</paragraph>
                        <paragraph>As with other NSAIDs, the lowest effective dose should be sought for each patient. In chronic conditions, a therapeutic response to therapy with etodolac extended-release tablets is sometimes seen within one week of therapy, but most often is observed by two weeks.</paragraph>
                     </text>
                     <effectiveTime value="20140210"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID165">
               <id root="5d135044-602a-180a-e053-2991aa0ab763"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Etodolac Extended-release Tablets USP, 600 mg are blue-colored, oval-shaped, beveled edged, film-coated tablets debossed with "273" on one side and plain on other side and are supplied repackaged as follows:</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Storage:</content>
                  </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</paragraph>
                  <paragraph>Protect from excessive heat and humidity.</paragraph>
                  <paragraph>Dispense in a tight, light-resistant container with a child-resistant closure.</paragraph>
               </text>
               <effectiveTime value="20140210"/>
            </section>
         </component>
         <component>
            <section ID="ID211">
               <id root="5d135044-602b-180a-e053-2991aa0ab763"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <paragraph ID="ID168">
                     <content styleCode="bold">Medication Guide</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Etodolac </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(e-TOE-doe-lak)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Extended-release </content>
                     <content styleCode="bold">Tablets</content>
                     <content styleCode="bold">, USP</content>
                  </paragraph>
                  <paragraph ID="ID170">
                     <content styleCode="bold">What is the most important information I should know about medicines called Nonsteroidal Anti- inflammatory Drugs (NSAIDs)? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAIDs can cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Increased risk of a heart attack or stroke that can lead to death</content> . This risk may happen early in treatment and may increase:
       
 
  </item>
                  </list>
                  <paragraph ID="ID221">○   with increasing doses of NSAIDs </paragraph>
                  <paragraph>○   with longer use of NSAIDs </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take NSAIDs right before or after a heart surgery called a "coronary artery bypass graft (CABG)." Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack.</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Increased risk      of bleeding, ulcers, and tears (perforation) of the esophagus (tube      leading from the mouth to the stomach), stomach and intestines: </content>
                     </item>
                  </list>
                  <paragraph ID="ID213"> </paragraph>
                  <paragraph>○   anytime during use </paragraph>
                  <paragraph>○   without warning symptoms </paragraph>
                  <paragraph>○   that may cause death </paragraph>
                  <paragraph>
                     <content styleCode="bold">The risk of getting an ulcer or bleeding increases with:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>past history of stomach ulcers, or stomach or      intestinal bleeding with use of NSAIDs</item>
                     <item>taking medicines called "corticosteroids", "anticoagulants",      "SSRIs", or "SNRIs</item>
                     <item>increasing doses of NSAIDs</item>
                     <item>longer use of NSAIDs</item>
                     <item>smoking</item>
                     <item>drinking alcohol</item>
                     <item>older age</item>
                     <item>poor health</item>
                     <item>advanced liver disease</item>
                     <item>bleeding      problems</item>
                  </list>
                  <paragraph ID="ID180"> 
       
 
  <content styleCode="bold">NSAIDs should only be used:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>exactly as prescribed</item>
                     <item>at the lowest dose possible for your treatment</item>
                     <item>for the shortest      time needed</item>
                  </list>
                  <paragraph ID="ID183">
                     <content styleCode="bold">What are NSAIDs? </content>
                  </paragraph>
                  <paragraph>NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take NSAIDs? Do not take NSAIDs:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>if you have had an asthma attack, hives, or other      allergic reaction with aspirin or any other NSAIDs.</item>
                     <item>right      before or after heart bypass surgery.</item>
                  </list>
                  <paragraph ID="ID214">
                     <content styleCode="bold">Before taking NSAIDS, tell your healthcare provider about all of your medical conditions, including if you:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>have liver or kidney problems</item>
                     <item>have high blood pressure</item>
                     <item>have asthma</item>
                     <item>are pregnant or plan to become pregnant. Talk to your      healthcare provivder if you are considering taking NSAIDs during      pregnancy. 
        
  
   <content styleCode="bold">You should not take NSAIDs after 29 weeks of pregnancy. </content>
                     </item>
                     <item>are      breastfeeding or plan to breast feed
        
  
   <content styleCode="bold">. </content>
                     </item>
                  </list>
                  <paragraph ID="ID215">
                     <content styleCode="bold">Tell your healthcare provider about all of the medicines you take, including prescription or over-the- counter medicines, vitamins or herbal supplements. </content>NSAIDs and some other medicines can interact with each other and cause serious side effects. 
       
 
  <content styleCode="bold">Do not start taking any new medicine without talking to your healthcare provider first. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of NSAIDs? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAIDs can cause serious side effects, including: </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">See "What is the most important information I should know about medicines called Nonsteroidal Anti- inflammatory Drugs (NSAIDs)?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>new or worse high blood pressure</item>
                     <item>heart failure</item>
                     <item>liver problems including liver failure</item>
                     <item>kidney problems including kidney failure</item>
                     <item>low red blood cells (anemia)</item>
                     <item>life-threatening skin reactions</item>
                     <item>life threatening allergic reactions</item>
                     <item>
                        <content styleCode="bold">Other      side effects of NSAIDs include: </content> stomach pain, constipation, diarrhea,      gas, heartburn, nausea, vomiting, and dizziness.
       
 
  </item>
                  </list>
                  <paragraph ID="ID217">
                     <content styleCode="bold">Get emergency help right away if you get any of the following symptoms:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>shortness of breath or trouble breathing</item>
                     <item>chest pain</item>
                     <item>weakness in one part or side of your body</item>
                     <item>slurred speech</item>
                     <item>swelling      of the face or throat</item>
                  </list>
                  <paragraph ID="ID193">
                     <content styleCode="bold">Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>nausea</item>
                     <item>more tired or weaker than usual</item>
                     <item>diarrhea</item>
                     <item>itching</item>
                     <item>your skin or eyes look yellow</item>
                     <item>indigestion or stomach pain</item>
                     <item>flu-like symptoms</item>
                     <item>vomit blood</item>
                     <item>there is blood in your bowel movement or it is black and sticky like      tar</item>
                     <item>unusual weight gain</item>
                     <item>skin rash or blisters with fever</item>
                     <item>swelling of the      arms, legs, hands and feet</item>
                  </list>
                  <paragraph ID="ID196">
                     <content styleCode="bold">If you take too much of your NSAID, call your healthcare provider or get medical help right away. </content>
                  </paragraph>
                  <paragraph>These are not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs. </paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Other information about NSAIDs</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines.</item>
                     <item>Some NSAIDs are sold in lower doses without a prescription (over-the counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</item>
                  </list>
                  <paragraph ID="ID198">
                     <content styleCode="bold">General information about the safe and effective use of NSAIDs </content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them. </paragraph>
                  <paragraph>If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals. </paragraph>
                  <paragraph>Please address medical inquiries to, (MedicalAffairs@zydususa.com) Tel.: 1-877-993-8779. </paragraph>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration. </paragraph>
                  <paragraph>
                     <content styleCode="bold">This product's package insert may have been updated. For current package insert, please visit www.zydususa.com</content>
                  </paragraph>
               </text>
               <effectiveTime value="20160607"/>
            </section>
         </component>
         <component>
            <section ID="ID204">
               <id root="5d135044-602c-180a-e053-2991aa0ab763"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 70332-320-01 repackaged as 7 tablets</paragraph>
                  <paragraph/>
                  <paragraph>Etodolac Extended-release Tablets USP, 600 mg</paragraph>
                  <paragraph>R 
  <sub>x </sub>only
 </paragraph>
                  <paragraph>7 tablets</paragraph>
                  <paragraph>Manufactured by: ZYDUS</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_55dec89e-05ca-5f55-e054-00144ff88e88"/>
                  </paragraph>
                  <paragraph>NDC 70332-320-02 repackaged as 30 tablets</paragraph>
                  <paragraph/>
                  <paragraph>Etodolac Extended-release Tablets USP, 600 mg</paragraph>
                  <paragraph>R x only</paragraph>
                  <paragraph>7 tablets</paragraph>
                  <paragraph>Manufactured by: ZYDUS</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_55df1359-3be8-20bf-e054-00144ff8d46c"/>
                  </paragraph>
               </text>
               <effectiveTime value="20170629"/>
               <component>
                  <observationMedia ID="img_55dec89e-05ca-5f55-e054-00144ff88e88">
                     <text>CS174-A1 Repackaged Etodolac</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="CS174-A1 Repackaged Etodolac.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_55df1359-3be8-20bf-e054-00144ff8d46c">
                     <text>CS174-A2 Repackaged Etodolac</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="CS174-A2 Repackaged Etodolac.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>